{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-148212","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2023-05-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.417145+00:00","generated_at":"2026-06-14T21:22:40.159517+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cabaletta Bio prices $87M public offering of 7.25M shares at $12.00 per share","bullets":["Pricing of 7,250,000 shares at $12.00 per share; gross proceeds expected $87M before expenses.","Underwriters granted 30-day option for up to an additional 1,087,500 shares.","Net proceeds estimated at $81.18M after underwriting discounts and offering expenses.","Proceeds to fund expanded clinical development of CABA-201, manufacturing, and CAART programs.","Offering expected to close May 22, 2023; TD Cowen, Evercore ISI, Guggenheim lead."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-148212","json":"https://secwatch.observer/filing/0001193125-23-148212.json","markdown":"https://secwatch.observer/filing/0001193125-23-148212.md","text":"https://secwatch.observer/filing/0001193125-23-148212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523148212/0001193125-23-148212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523148212/d408961d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T21:22:40.159517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40f046cf3110a3f5ea04a62f58d2b8dded84e63b","claim":"Cabaletta Bio, Inc. entered into Underwriting Agreement with Cowen and Company, LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC valued at 7,250,000 shares of common stock at $12.00 per share, option for additional 1,087,500 shares (effective 2023-05-17).","evidence_excerpt":"On May 17, 2023, Cabaletta Bio, Inc. (the “Company” or “Cabaletta”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC (collectively, the “Underwriters”), related to a public offering (the “Offering”) of 7,250,000 shares of common stock of the Company, par value $0.00001 per share (the “Common Stock”) at a price to the public of $12.00 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523148212/0001193125-23-148212-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Cowen and Company, LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC"},{"label":"Value","value":"7,250,000 shares of common stock at $12.00 per share, option for additional 1,087,500 shares"},{"label":"Effective","value":"2023-05-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}